Trial NCT03584009

View at ClinicalTrials.gov 
Org. Study IDs: WO40181
Secondary IDs: 2017-005118-74

Last trial update was posted on 2022-06-28

MeSH Interventions

Fulvestrant Venetoclax

MeSH Conditions

Breast Neoplasms Recurrence

Other Conditions

Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

Stopping Reasons

Sponsor's decision, no safety concerns.

Limitations And Caveats

The study was terminated due to Sponsor's decision and there were no safety concerns. Primary and secondary efficacy endpoints have been updated to report 95% confidence interval (CI) for Clinical Benefit estimate and 95% CI for the Cox proportional hazards model for PFS, following reporting conventions.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID